Creating new ways to prevent HIV-1 infection using advanced antibodies
Development of a Next-Generation Immunoprevention Platform Against HIV-1
This study is working on new ways to deliver special antibodies that can help prevent HIV-1 infection, especially for women, by making them stronger and longer-lasting, so they can better protect against different types of the virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neovaxsyn, INC. NIH-funded |
| Lab location | 1 site (Ames, United States) |
| Project ID | NIH-11171823 on NIH RePORTER |
What this research studies
This research focuses on developing innovative platforms for administering broadly neutralizing antibodies (bNAbs) to prevent HIV-1 infection. By enhancing the potency and longevity of these antibodies, the project aims to improve their effectiveness against the diverse strains of HIV-1. The approach includes engineering new devices and materials that can deliver these antibodies more efficiently, particularly in the female vaginal tract, to provide better protection from infection. The research builds on previous successful trials and seeks to address challenges related to drug delivery and formulation.
Who could benefit from this research
Good fit: Ideal candidates for this research are women at high risk of HIV-1 exposure who may benefit from enhanced preventive measures.
Not a fit: Patients who are already HIV-positive or those who do not have risk factors for HIV-1 infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of HIV-1 infection, particularly in high-risk populations.
How similar studies have performed: Previous studies, such as the Antibody Mediated Prevention (AMP) trials, have shown promise in using broadly neutralizing antibodies for HIV prevention, indicating a potential for success in this novel approach.
Where this research is happening
Ames, United States
- Neovaxsyn, INC. — Ames, United States (Active)
Researchers
- Principal investigator: Raychaudhuri, Santanu — Neovaxsyn, INC.
- Study coordinator: Raychaudhuri, Santanu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.